US Edition
Real-world data backs anti-IL-5 use in COPD with comorbid asthma - Express Pharma
Summary by Express Pharma
This story is only covered by news sources that have yet to be evaluated by the independent media monitoring agencies we use to assess the quality and reliability of news outlets on our platform. Learn more here.1 Articles
1 Articles
All
Left
Center
Right
Real-world data backs anti-IL-5 use in COPD with comorbid asthma - Express Pharma
Anti–IL-5 biologics, such as mepolizumab and benralizumab, have demonstrated significant efficacy in reducing moderate and severe exacerbations in patients with both asthma and chronic obstructive pulmonary disease (COPD), according to new real-world data presented at the 2025 American Thoracic Society (ATS) International Conference. These findings reinforce the therapeutic potential of eosinophil-targeting agents in patients with overlapping re…
Coverage Details
Total News Sources1
Leaning Left0Leaning Right0Center0Last UpdatedBias DistributionNo sources with tracked biases.
Bias Distribution
- There is no tracked Bias information for the sources covering this story.
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
